For women with a pelvic mass, the diagnostic path for ovarian cancer is a slow, uncertain gauntlet. Imaging is often inconclusive, and the standard blood test for the protein CA-125 is notoriously unreliable. AOA Dx, a Denver-based biotech, is betting that a different class of molecule found in blood, long overlooked by diagnostics, can bring clarity to that fraught moment. Its lead test, AKRIVIS GD, looks for tumor-derived gangliosides, a type of glycolipid, using a multi-omics and AI platform called GlycoLocate. The company's $17 million Series A, led by Good Growth Capital last October, is a vote of confidence that this biochemical niche could be a clinical breakthrough [Crunchbase, 2026].
The ganglioside wedge
The bet rests on a simple, if scientifically challenging, premise. While most liquid biopsies for cancer hunt for circulating tumor DNA or proteins like CA-125, AOA Dx is focused on gangliosides. These complex lipids are abundant on the surface of cancer cells and are shed into the bloodstream, but they have been historically difficult to detect and analyze at scale. The company's GlycoLocate platform uses machine learning to parse a multi-omics signature from a blood sample. In its own studies, the company reports its model achieved an area under the curve (AUC) of 0.969 for detecting ovarian cancer in early stages, with a sensitivity of 94.8% for early-stage disease [AOA DX, 2026].
The team and the capital runway
AOA Dx was founded in 2020 by Oriana Papin-Zoghbi, Alexander Fisher, and Anna Jeter. Papin-Zoghbi, the CEO, has become a public voice for the company's mission in women's health, while Fisher serves as COO and Jeter as Chief Regulatory Officer [theorg.com, 2026]. The team's collective experience, described as spanning over 30 years in bringing medical technologies from concept to global markets, is now being tested on the complex regulatory path for a novel in vitro diagnostic [Growjo, 2026].
| Role | Name | Notes |
|---|---|---|
| CEO & Co-Founder | Oriana Papin-Zoghbi | Public face of the company; frequent speaker on women's health diagnostics. |
| COO & Co-Founder | Alexander Fisher | Leads operations and commercial strategy. |
| Chief Regulatory Officer & Co-Founder | Anna Jeter | Guides the product through FDA and other regulatory pathways. |
The competitive and clinical landscape
The field of early cancer detection is crowded, but the focus on ovarian cancer, and specifically on symptomatic women, carves out a distinct lane. Competitors like Mercy BioAnalytics and Dxcover are also developing liquid biopsies, but they often utilize different biomarker strategies or target different cancer types. AOA Dx's differentiation is its foundational research into gangliosides, which it frames as a new biomarker class for oncology diagnostics.
The risks on the road to market
Every novel diagnostic faces a gauntlet of validation, and AOA Dx's ganglioside-based approach is no exception. The risks are not subtle:
- Biomarker reproducibility. Ganglioside signatures can be influenced by factors beyond cancer, including other inflammatory conditions.
- Regulatory pathway. The FDA's standards for a diagnostic test claiming to detect ovarian cancer are stringent.
- Market adoption. Convincing oncologists and gynecologists to change practice requires overcoming deep-seated clinical inertia.
What to watch in the next 12 months
The coming year is likely to be defined by clinical milestones. The most significant will be the initiation and design of the pivotal validation study for AKRIVIS GD. Concurrently, watch for peer-reviewed data submissions to journals. External validation is the currency of credibility in this field. Financially, the $17 million Series A provides a runway, but the costs of a pivotal trial can quickly consume eight figures. Partnership news would also be a strong signal; a collaboration with a large diagnostic player or a healthcare system for clinical trial recruitment would de-risk the path forward.